Eyenovia’s Optejet Device Demonstrates Exceptional Microbial Integrity in Rigorous Testing

Eyenovia, a leading ophthalmic technology company, is set to present its groundbreaking findings on the microbial integrity of its Optejet dispensing device at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual Meeting. The study showcases the Optejet’s ability to maintain product sterility even when exposed to a microbial load that exceeds typical environmental conditions.

Recent studies have highlighted the high contamination rates of both preserved and preservative-free multi-use eye drops, reaching as high as 94%. This alarming statistic emphasizes the urgent need for a next-generation topical ophthalmic drug dispensing device that can administer medication without preservatives or contaminants, which can be harmful to the eye.

Eyenovia’s Optejet device has successfully demonstrated its ability to remain contaminant-free, even under rigorous testing conditions. This breakthrough paves the way for the delivery of preservative-free medications, offering significant long-term benefits to patients.

Michael Rowe, the CEO of Eyenovia, expressed his enthusiasm for the study’s results, stating, “This study successfully demonstrates the Optejet’s ability to maintain product sterility even when exposed to a microbial load that exceeds typical environmental conditions, supporting the potential for the Optejet to be used to deliver preservative-free medications.”

Eyenovia is a commercial-stage ophthalmic pharmaceutical technology company that focuses on developing microdose array print therapeutics based on its Optejet platform. The company is currently focused on commercializing Mydcombi, a product for mydriasis, and is preparing for the regulatory approval of APP13007, a medication designed to relieve pain and inflammation post ocular surgery.

In addition to these advancements, Eyenovia is also incorporating its advanced Optejet device with late-stage product candidates for presbyopia and pediatric progressive myopia. The company is actively exploring out-licensing opportunities for additional indications.

The presentation at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual Meeting will shed light on Eyenovia’s commitment to revolutionizing ophthalmic drug delivery and ensuring patient safety. The Optejet device’s exceptional microbial integrity sets a new standard for the industry, offering a promising solution to the contamination issues faced by traditional eye drop dispensers.

For more information about Eyenovia and its innovative ophthalmic technologies, visit Eyenovia.com.